$NMRD – Nemaura Medical, Inc., promotional campaign starting Sep 19, 2021 @ 3:01 PM CST

on September 19, 2021 Stock Promotion Tracking and Tags: , , , , , , , , , with 0 comments


Start time:
3:01 PM
Start date:
September 19, 2021
Nemaura Medical, Inc.
Stock promoter:
Stock promoter rank:
13 out of 24
Promoter score:
Campaign ID:

Nemaura Medical, Inc.

Market capitalization:
(as of August 31, 2021)
Outstanding shares:
(as of August 28, 2021)
Authorized shares:
(as of August 28, 2021)

Stock Promoter Performance

The following charts displays the first day results for campaigns by "Tip". Results are taken from a total of 21 stock promotions by this stock promoter that have been tracked by OTC Dynamics.
35% closed down

41% closed up

23% had no net effect

Last 3 Stock Promotions By "Tip"

Symbol Company Start Date Close Change
FDBL Friendable, Inc. September 6, 2021 0.0083 -1%
MCURF Mind Cure Health Inc. August 29, 2021 0.306 2%
DELCF Delic Holdings Inc. August 22, 2021 0.225 3%

NMRD Promotional Newsletter

The following is a newsletter released by "Tip" promoting Nemaura Medical, Inc.


The following newsletter has not been verified for accuracy or completeness.

Nemaura Medical Inc.NASDAQ NMRD

Nemaura Medical Inc. NASDAQ is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Its flagship product, sugarBEAT, is a wearable, non-invasive and flexible Continuous Glucose Monitor CGM designed to help people with diabetes and prediabetes manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.

sugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with a smartphone app displaying glucose readings at five-minute intervals for periods of up to 24 hours. One of the great advantages of the product, apart from the fact that users no longer need to draw blood samples or prick their fingers, is that a person can wear the CGM patch on whatever day they choose. Existing CGM devices must be implanted under the skin. Wearable disposability is a unique feature of sugarBEAT and a world first, opening up vast potential for changing the way people manage their chronic disease conditions. sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union as a Class 2b Medical Device. The company submitted a premarket approval PMA application to the U.S. Food and Drug Administration in 2020 which is currently under review.

Founded in 2011, Nemaura set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and well-being. Nemauras skin surface blood monitoring technology has allowed the company to create additional products, which are in the pipeline, such as Lactate Monitoring.

Recent Coverage

InvestorNewsBreaks - Nemaura Medical Inc. NASDAQ NMRD Names World-Renowned Thought Leader as Advisory Board Member

September 17, 2021 945 AM

, a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that Dr. Osama Hamdy, MD, PhD, has joined its advisory board. Hamdy will act as a consultant and will provide invaluable input regarding key opinion leader studies in both the diabetes and metabolic health fields using Nemauras glucose monitoring technology. An acclaimed endocrinologist, Hamdy is medical director of the Obesity Clinic Program at the Joslin Diabetes Center he is also an associate professor of medicine at Harvard Medical School. He has built a stellar reputation as a world-renowned thought leader in obesity management in diabetes, medical nutrition and digital health, and has impacted the space through many discoveries and innovations. He provides expertise in understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss with current research in the cardiovascular benefits of short- and long-term weight reduction in obese individuals with and without type 2 diabetes. We are truly gratified to have a practicing clinician that has changed the real-world treatment of diabetes management as an advisor to us for some upcoming KOL studies, said Nemaura CEO Dr. Faz Chowdhury in the press release. These studies will allow us to better impact patient health, and we expect the counsel and input from Dr. Hamdy to be meaningful in helping us to deliver non-invasive treatment options to further enrich peoples lives.

Other companies we are watching

Tip Us Off

Know of a stock poised to make a big move Tell us which one and why We're constantly scanning the headlines and keeping tabs on what's hot, but can always use an extra hand. Whether amateur or pro, you're more than welcome to join in on the fun

Sign Up For Instant Alerts

Micro-cap stocks can make rapid moves of 50% or more, making the latest information extremely critical to maximizing profits.

Please read for FULL Compensation Disclosures and other disclaimers.
Copyright 2012-2018.

Get Every Penny Stock Alert!

OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!

Sign up today!


OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.

The information on this page is not a recommendation to buy or sell securities.